AGEN.NASDAQAgenus INC

Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Sentiment:

SEC Form 4 Filing


Agenus Inc. CEO Garo H. Armen received 973 shares of common stock as part of his salary in lieu of cash, according to a recent SEC Form 4 filing.

Summary

  • Garo H. Armen, CEO of Agenus Inc., received 973 shares of Agenus common stock on June 28, 2024, as part of his salary in lieu of cash.
  • The stock was issued at a price of $16.75 per share, which was the closing price of Agenus common stock on that date.
  • These shares were issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive and are fully vested upon issuance.
  • Following this transaction, Armen directly owns 75,615 shares and indirectly owns 31,298 shares through IRA accounts and 28,950 shares as trustee and investment authority for the Garo Armen 2020 2 Year AG GRAT and as a general partner in Pixie Partners.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing a stock transaction. It doesn't contain overtly positive or negative information, but the CEO taking salary in stock could be seen as a mildly positive signal.

Positives

  • The CEO's decision to take salary in stock may signal confidence in the company's future performance.
  • The stock is fully vested upon issuance, aligning the CEO's interests with those of the shareholders.

Industry Context

It is not uncommon for executives, especially in biotech companies, to receive stock as part of their compensation packages. This aligns their interests with shareholders and incentivizes them to increase the company's value.

Comparison to Industry Standards

  • Stock-based compensation is a common practice among publicly traded companies, particularly in the biotechnology sector.
  • Companies like Amgen, Gilead Sciences, and Biogen often use stock options and restricted stock units as part of their executive compensation packages to align management's interests with those of shareholders.
  • The specific amount and vesting schedule of stock-based compensation vary widely depending on the company's size, performance, and industry standards.

Stakeholder Impact

  • Shareholders may view the CEO accepting stock in lieu of cash as a positive sign of confidence in the company's future.
  • Employees may see this as a commitment from leadership to the long-term success of the company.

Key Dates

DateDescription
06/14/2024End of pay period for which stock was issued.
06/28/2024Date of transaction (stock grant) and payroll date.
07/01/2024Date of signature on the SEC Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.